Vladimir Gusinsky Revocable Trust v. Mahoney Alleges Misleading Proxy Statements Before a $24 Billion Market Loss
The Vladimir Gusinsky Revocable Trust has filed a stockholder derivative complaint against Boston Scientific Corporation, citing alleged breaches of fiduciary duties in relation to battery defects found in the company's ACCOLADE pacemakers. The filing accuses the corporation and its officers of failing to disclose significant safety and financial risks tied to these medical devices, which allegedly resulted in four patient deaths and 2,557 serious injuries. The allegations center on the company's purported omissions and false statements in public disclosures, including SEC filings and press releases, calling for restitution for shareholder losses and demanding corporate governance reforms.
Step-by-Step Alleged Cover-up Mechanism
The complaint alleges that executives, including Michael F. Mahoney and Jonathan R. Monson, failed to disclose critical safety and financial risks linked to the ACCOLADE pacemakers. These failures allegedly occurred despite internal battery tests conducted at the Arden Hills Facility from 2019 to 2023, which revealed significant defects. These issues eventually led to public advisories and FDA Class I recalls affecting approximately 1.6 million devices.
According to the complaint, the inaccuracies in communications extended to SEC filings and press releases, where the defendants purportedly made materially false and misleading statements. The allegations suggest a systematic concealment of adverse facts from the public, specifically concerning the battery defects that reportedly caused four patient deaths and 2,557 serious injuries.
The plaintiffs argue that the defendants' actions constituted violations of fiduciary duties, primarily by failing to ensure truthful disclosures about the safety risks and financial liabilities associated with the ACCOLADE pacemakers. This omissive behavior purportedly misled investors, contributing to a market capitalization loss when these risks were later disclosed.
Financial Impact and Alleged Misstatements
The complaint alleges that Boston Scientific Corporation's failure to disclose the risks associated with its ACCOLADE pacemakers resulted in a significant financial impact, including a $24 billion market capitalization loss. This decline, representing a 17.6% drop in stock value, occurred on February 4, 2026, following the release of the company’s fourth-quarter earnings report. The plaintiff claims this loss was largely attributable to the defendants' alleged concealment of the defects and subsequent recalls related to the ACCOLADE pacemakers.
During the third quarter of 2025, Boston Scientific reported net sales of $5.065 billion and GAAP net income of $755 million, with a GAAP EPS of $0.51 and adjusted EPS of $0.75. The company subsequently raised its full-year guidance to a GAAP EPS range of $1.97 to $2.01. In results announced on February 4, 2026, the company reported full-year 2025 net sales of $20.074 billion and GAAP net income of $2.898 billion, corresponding to a GAAP EPS of $1.94. However, the fourth-quarter results of 2025 fell short, noting GAAP net income of $672 million with EPS of $0.45, below the guidance EPS range of $0.48–$0.52 (Compl. ¶68). Such discrepancies contributed to the narrative of misleading the company's financial disclosures.
Additionally, the complaint criticizes Boston Scientific for omitting crucial details regarding product recalls and associated liabilities in its Q1 2026 earnings release. Despite the gravity of the recalls and their implications, the release failed to address these matters, which, the plaintiff alleges, deprived stakeholders of a clear view of the company's true financial condition. Such omissions, according to the complaint, contravened the company's disclosure obligations and contributed to the continued misleading narrative presented to investors.
Key Parties and Defendants
The lawsuit filed by the Vladimir Gusinsky Revocable Trust names Boston Scientific Corporation as the nominal defendant. The company is accused of allowing significant safety failures and financial risks concealed from shareholders, notably relating to the ACCOLADE family pacemakers. The trust alleges that the corporation's failure to adequately disclose these risks has harmed shareholders and violated fiduciary duties.
The complaint identifies several individual defendants within Boston Scientific's leadership who are said to bear responsibility for these alleged failures. Michael F. Mahoney, CEO and a director since 2012 and Chairman of the Board since May 2016, is listed as a key figure among them. Jonathan R. Monson, who assumed the role of CFO in June 2025, is also named as a defendant. Both executives are accused of overseeing misleading communications about the company's financial standing and risk management practices.
In addition to executive officers, the complaint targets several board members, emphasizing their oversight roles. These include Jessica L. Mega, a director who joined in June 2023. The complaint also names Kenneth M. Stein, the company's Global Chief Medical Officer, as an officer defendant. Each individual defendant is accused of failing to uphold their fiduciary responsibilities by not properly addressing or disclosing the known battery defects and associated risks, which led to significant corporate and patient consequences.
The plaintiff alleges that these leadership figures, alongside other board members such as John E. Sununu and Yoshiaki Fujimori, who recently concluded their directorships, were responsible for inadequate internal controls and corporate governance that failed to prevent the ensuing disclosures and financial fallout.
These allegations remain unproven at the current stage of the litigation, and no responses from the defendants have been recorded. Boston Scientific has been alleged to have bypassed critical oversight, misled investors, and allowed misrepresentation of financial reports and product safety risks, impacting the company's valuation and shareholder trust.
Violations of Securities Exchange Act and Fiduciary Duties
The Verified Stockholder Derivative Complaint filed by the Vladimir Gusinsky Revocable Trust against Boston Scientific Corporation includes claims that the company and its directors violated Section 14(a) of the Securities Exchange Act of 1934, as well as Rule 14a-9, by issuing false and misleading proxy statements. The complaint alleges that these statements failed to accurately disclose significant issues concerning the ACCOLADE pacemaker's battery defect, which led to multiple FDA recalls, four deaths, and 2,557 serious injuries. The omissions and misrepresentations in the company's proxy materials purportedly misled stockholders regarding the integrity of the company's risk management and product safety oversight systems.
The plaintiff further contends that the individual defendants are liable under Section 20(a) of the Securities Exchange Act of 1934, which addresses control person liability. According to the complaint, the individual directors held positions of power within the company and had control over the company’s SEC filings and public disclosures. The complaint asserts that these directors knew of the adverse facts regarding the battery failures, yet failed to disclose these to stockholders and the public (Compl. ¶34). As control persons, they are alleged to have failed their duty to prevent the dissemination of false and misleading information, thereby contributing to the company's substantial market capitalization loss.
These allegations form a core part of the lawsuit's demands for reform and restitution, as the stockholder seeks to enforce stronger compliance with securities laws and corporate governance standards to prevent future occurrences of similar issues.
Breach of Fiduciary Duty and Unjust Enrichment
The complaint filed by Vladimir Gusinsky Revocable Trust accuses the individual defendants of breaching their fiduciary duties, which include duties of loyalty, good faith, and candor, by failing to remedy misleading statements and by disregarding significant red flags related to Boston Scientific Corporation's ACCOLADE pacemakers. The complaint alleges that these defendants controlled the company's communications with shareholders, including SEC filings and press releases, and knew they were concealing adverse information from the public, rendering these communications materially false and misleading (Compl. ¶37-38).
Specifically, the complaint contends that the defendants failed in their oversight responsibilities by not ensuring that the company had adequate internal controls and Board-level reporting systems designed to provide timely notice of risks to product safety. These alleged failures extended to the handling of serious issues identified through internal battery tests, which were purported to have demonstrated defects leading to several FDA Class I recalls. The complaint emphasizes that the failure to act on such warnings resulted in significant patient harm, including four deaths and 2,557 injuries, as well as a substantial recall involving 1.6 million devices (Compl. ¶97).
Furthermore, the lawsuit asserts an unjust enrichment claim against the individual defendants, alleging they profited from their omissions and the dissemination of misinformation. This claim centers on the argument that the defendants' misconduct enabled them to retain and receive compensation and other incentives based on artificially inflated performance metrics and stock prices, which were not corrected to reflect the known risks and flaws in the company's product lines (Compl. ¶121).
The lawsuit seeks a declaration that the defendants have breached their fiduciary duties and demands restitution, including the disgorgement of any gains obtained through their alleged misconduct. Additionally, the complaint calls for comprehensive reforms to Boston Scientific's corporate governance practices to prevent future occurrences of similar issues.
Distinctive Allegations: Failed Oversight and Misleading Statements
The complaint alleges that the Individual Defendants of Boston Scientific Corporation failed to exercise appropriate oversight concerning the safety of the company's ACCOLADE pacemaker batteries. Despite being aware of the defects and subsequent recalls, as well as prior incidents leading to patient deaths and injuries, they purportedly did not take adequate measures to mitigate these risks. This oversight failure allegedly resulted in significant harm, including patient fatalities and thousands of injuries, as stated in the complaint.
Additionally, the complaint contends that Boston Scientific's proxy statements contained misleading representations regarding product safety oversight and governance practices. According to the plaintiff, these statements omitted critical information about the device failures, thereby misleading shareholders about the true state of risk management and the effectiveness of the company's internal controls (Compl. ¶102-104). The complaint asserts that the defendants falsely implied compliance with Boston Scientific's Code of Conduct, despite ongoing quality issues that contradicted such representations (Compl. ¶106).
The plaintiff argues that the failure to escalate known battery-test failures and prior recalls to the board level further illustrates an alleged breakdown in governance practices. This purported omission rendered the company's claims of robust product quality oversight as materially misleading, particularly in light of bonuses awarded to the executive team despite these safety failures.
Lastly, the alleged misleading statements in the proxy solicitations regarding board nominee re-elections are highlighted in the complaint. These statements are claimed to have misrepresented the diligence and effectiveness of the defendants in fulfilling their fiduciary duties, ultimately undermining the integrity of the shareholder solicitation process (Compl. ¶108).
Relief Sought and Procedural Posture
The verified stockholder derivative complaint filed by the Vladimir Gusinsky Revocable Trust seeks several forms of relief against the defendants. The complaint demands a declaratory judgment that the individual defendants breached their fiduciary duties to the company and its shareholders, as well as awards for damages jointly and severally from the defendants, accompanied by pre- and post-judgment interest. Additionally, the complaint seeks restitution and disgorgement to address alleged unjust enrichment by the defendants through their purported misconduct.
The plaintiffs also request substantial reforms to the corporate governance and internal procedures of Boston Scientific. These reforms aim to enhance the board's oversight of product safety and disclosures to prevent the recurrence of such alleged oversight failures in the future. The complaint emphasizes the need for enhanced board-level reporting systems to provide timely notice of mission-critical risks, addressing the alleged failures that led to significant financial and reputational harm to the company (Compl. ¶39-40).
Completing the relief sought, the plaintiffs demand costs, fees, and expenses incurred during the proceedings. A jury trial is also requested to address the issues raised in the complaint. However, specific procedural details, such as the case's current status or the identity of the presiding judge, were not specified in the filed document. These filings aim to ensure accountability and compliance with fiduciary obligations.
The allegations described here are taken from the filing and remain unproven; no responsive pleading is reflected in the source document.
Questions about this topic: david@newmanbrunk.com